Allspring Global Investments Holdings LLC Has $75.59 Million Stock Holdings in Danaher Corporation $DHR

Allspring Global Investments Holdings LLC lifted its position in shares of Danaher Corporation (NYSE:DHR) by 579.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 375,863 shares of the conglomerate’s stock after purchasing an additional 320,521 shares during the quarter. Allspring Global Investments Holdings LLC owned 0.05% of Danaher worth $75,586,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of DHR. Vanguard Group Inc. boosted its stake in Danaher by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate’s stock worth $12,296,123,000 after purchasing an additional 230,966 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Danaher by 3.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock valued at $4,016,404,000 after buying an additional 612,154 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Danaher by 2.3% in the 1st quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate’s stock valued at $1,800,614,000 after acquiring an additional 194,466 shares during the period. Invesco Ltd. increased its position in Danaher by 44.5% during the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock worth $965,259,000 after buying an additional 1,450,703 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Danaher by 4.0% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 4,230,087 shares of the conglomerate’s stock valued at $867,168,000 after purchasing an additional 163,332 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

DHR has been the topic of a number of recent research reports. Royal Bank Of Canada set a $241.00 price target on shares of Danaher in a research report on Tuesday, September 2nd. Bank of America lowered their target price on shares of Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a report on Monday, September 22nd. Scotiabank raised Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 price target on the stock in a research report on Friday, July 11th. Rothschild Redb lowered Danaher from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 8th. Finally, Barclays reaffirmed an “overweight” rating and issued a $225.00 price objective (up from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $244.60.

Danaher Price Performance

Shares of NYSE:DHR opened at $205.36 on Tuesday. Danaher Corporation has a one year low of $171.00 and a one year high of $279.41. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The company has a market cap of $147.05 billion, a price-to-earnings ratio of 43.69, a PEG ratio of 2.88 and a beta of 0.77. The firm has a 50 day simple moving average of $200.82 and a 200 day simple moving average of $197.06.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company’s revenue for the quarter was up 3.4% compared to the same quarter last year. During the same period in the prior year, the business earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Research analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be paid a $0.32 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. Danaher’s dividend payout ratio is currently 27.23%.

Insider Transactions at Danaher

In related news, Director Teri List sold 2,778 shares of Danaher stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director directly owned 20,751 shares in the company, valued at $4,379,706.06. This trade represents a 11.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 11.20% of the stock is currently owned by company insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.